Accelerating adherent cell production for diabetes gene therapy using a scalable fixed-bed bioreactor platform
Cell & Gene Therapy Insights 2022; 8(4), 601
DOI: 10.18609/cgti.2022.088
Published: 21 May 2022
FastFacts
Watch the video or read the poster to learn about:
- A novel fixed bed bioreactor specifically designed for high yield viral vector production from adherent cell lines
- How researchers at the Gittes Lab for Diabetes and Pancreatitis Research at the University of Pittsburgh Medical Center/Children’s Hospital of Pittsburgh demonstrated significant productivity gains using the Ascent FBR system for type 1 diabetes research
- How the Ascent FBR system enabled the Gittes lab to continuously monitor and control the temperature, pH, and DO of their HEK293 cells, resulting in higher viral productivity